Clinical Research Directory
Browse clinical research sites, groups, and studies.
COlorectal BReath Analysis (COBRA2)
Sponsor: Imperial College London
Summary
Colorectal cancer (CRC) is the second most common cause of cancer death in the United Kingdom, with approximately 17,000 deaths per year. The five-year survival rate from CRC is only 10% when discovered at a late stage, but exceeds 90% if diagnosed early. Symptoms related to CRC can be non-specific, therefore the decision to refer for a colonoscopy can be challenging. There is a clear need to improve earlier detection of CRC so that patients with CRC can be identified earlier and faster, enabling them to start treatment more quickly. The study team is developing a non-invasive breath test that detects small molecules called volatile organic compounds (VOCs) that are specific to CRC. For patients with non-specific symptoms, this test would help GPs to identify those patients that may have underlying CRC, who would benefit from referral for specialised CRC tests.
Official title: The COlorectal BReath Analysis (COBRA2) Study: Non-invasive Breath Testing to Detect Colorectal Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
720
Start Date
2022-09-23
Completion Date
2026-12-01
Last Updated
2025-06-13
Healthy Volunteers
Yes
Conditions
Interventions
Breath test
Patients must be fasted for a minimum of 4-6 hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
Locations (5)
Chelsea and Westminster Hospital
London, United Kingdom
Royal Marsden Hospital
London, United Kingdom
St Mark's Hospital
London, United Kingdom
St Mary's Hospital
London, United Kingdom
West Middlesex University Hospital
London, United Kingdom